CN116492240B - Compound chemical stripping skin-changing reagent containing baratinib and application thereof - Google Patents
Compound chemical stripping skin-changing reagent containing baratinib and application thereof Download PDFInfo
- Publication number
- CN116492240B CN116492240B CN202310786370.1A CN202310786370A CN116492240B CN 116492240 B CN116492240 B CN 116492240B CN 202310786370 A CN202310786370 A CN 202310786370A CN 116492240 B CN116492240 B CN 116492240B
- Authority
- CN
- China
- Prior art keywords
- skin
- changing
- chemical stripping
- mass
- baratinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims abstract description 77
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 41
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 claims abstract description 36
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000011975 tartaric acid Substances 0.000 claims abstract description 36
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 36
- 206010000496 acne Diseases 0.000 claims abstract description 24
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000012153 distilled water Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- -1 polydimethylsiloxane Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 9
- 206010067484 Adverse reaction Diseases 0.000 abstract description 8
- 230000006838 adverse reaction Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 61
- 230000000052 comparative effect Effects 0.000 description 36
- 206010040844 Skin exfoliation Diseases 0.000 description 22
- 229940051841 polyoxyethylene ether Drugs 0.000 description 18
- 229920000056 polyoxyethylene ether Polymers 0.000 description 18
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000001815 facial effect Effects 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 239000008407 cosmetic solvent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000008063 pharmaceutical solvent Substances 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010024121 Janus Kinases Proteins 0.000 description 3
- 102000015617 Janus Kinases Human genes 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002910 effect on acne Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of medical cosmetics, and particularly relates to a compound chemical stripping skin-changing reagent containing baratinib and application thereof. Experimental results show that the compound chemical stripping skin-changing reagent provided by the invention has the advantages that tartaric acid, phenethyl resorcinol and baratinib are combined in a specific proportion, a strong synergistic effect is shown on the aspect of chemical stripping skin-changing, the concentration of the tartaric acid and the phenethyl resorcinol in a formula can be reduced, a remarkable acne-removing skin-changing effect is obtained, and a remarkable synergistic effect is realized on treating acne. And the use is safe, the irritation to skin is small, and the adverse reaction is obviously reduced.
Description
Technical Field
The invention belongs to the technical field of medical cosmetics, and particularly relates to a compound chemical stripping skin-changing reagent containing baratinib and application thereof.
Background
Chemical stripping skin-changing technology is to apply chemical agent with skin burning effect to skin surface to cause skin to be destroyed and stripped controllably to promote new skin regeneration and to make melanin distribution even. The chemical stripping skin-changing is superior to the laser skin-changing in uniformity and planarity; the skin on the surface is not immediately removed, but only chemically necrotizes, and gradually falls off after the skin below is regenerated, so that the wound is simple to care. Chemical skin replacement may be for therapeutic or cosmetic purposes, and in general, by promoting aging, exfoliation of damaged stratum corneum, regeneration of epidermis and remodeling of dermis.
Indications for chemical stripping and skin replacement include skin texture problems, abnormal pigments and photoaging, most commonly used in the treatment of acne, scars, abnormal pigments and photoaging of the skin. According to statistics, 90% of teenagers have acne with different degrees, and the scholars summarize epidemiological investigation results of all areas of the world, the prevalence rate of the acne is between 70% and 87%, and no statistical difference exists among different ethnicities of different countries. Although many related acne treatment medicines and treatment methods are available, the most effective medicines used at present mainly comprise antibiotics, antiandrogens and tretinoin, but the more the hormone medicines are used, the more the hormone medicines have certain hormone dependence and side effects, so the search for a simple and effective method for treating acne is urgent. With the development of economy, more and more people begin to pay attention to the appearance and skin problems, and with the improvement of the living standard of people, chemical skin replacement is more and more favored by consumers and doctors.
Currently, common chemical exfoliating skin-changing agents include retinoic acid, trichloroacetic acid, phenol, resorcinol, jessner's solutions (resorcinol, salicylic acid, mixed solutions of lactic acid and ethanol), fruit acids such as lactic acid, glycolic acid, salicylic acid, tartaric acid, malic acid, citric acid, and the like. When peeling and skin changing are performed by using chemical substances, various adverse reactions are easily caused, and the adverse reactions include: erythema, itching, swelling, stinging, a sense of stretch of facial skin, a slight burning sensation, transient pigmentation, erosion, and the like. The chemical stripping and skin changing can cause damage to the barrier function of the skin while treating diseases, thereby causing the reduction of the skin resistance and increasing the probability of wound infection. Therefore, it is necessary to search for a novel skin peeling and changing agent having a clear clinical effect and less adverse reaction.
The combined skin change can reach deeper stripping degree by utilizing the synergistic effect of various chemical stripping skin change agents, can reduce the use concentration of the chemical stripping skin change agents, reduce adverse reactions caused after skin change, and simultaneously furthest avoid the risk of complications. Generally, the skin needs to be subjected to anti-inflammation and antioxidation after the skin is chemically stripped and changed, so that redness, itching, stinging, color spots, deposition and infection generated after the skin is changed are prevented, the existing mode is to adopt products with the effects after the skin is chemically stripped and changed, and the products with the effects of anti-inflammation and antioxidation are combined with less products.
Baratinib, chemical name 1- (ethylsulfonyl) -3- [4- (7H-pyrrolo [2, 3-D ] pyrimidin-4-yl) -1H-pyrazol-1-yl ] -3-azetidinylacetonitrile, is a selective JAK1/JAK2 inhibitor developed by american gift pharmaceutical company in cooperation with Incyte pharmaceutical company, janus kinase (JAK) is a family of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families do not possess catalytic kinase activity, they rely on the JAK tyrosine kinase family to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The baratinib can inhibit intracellular signaling of various inflammatory cytokines such as IL-6 and IL-23, and can be used for treating autoimmune diseases and related inflammations, such as rheumatoid arthritis, atopic dermatitis, psoriasis, diabetic nephropathy, etc.
Tartaric acid and phenethyl resorcinol are more commonly used chemical stripping skin-changing reagents, and phenethyl resorcinol also has the effects of whitening skin and lightening spots, but when the chemical stripping skin-changing is carried out by singly using high-concentration tartaric acid or high-concentration phenethyl resorcinol, the skin irritation is larger and the adverse reaction is more. The applicant of the invention surprisingly discovers that tartaric acid, phenethyl resorcinol and baratinib are combined in a specific proportion, and the combination shows a strong synergistic effect in terms of chemical stripping and skin replacement, can reduce the concentration of tartaric acid and phenethyl resorcinol in a formula, obtain obvious acne-removing skin-changing effects, also has skin whitening, antioxidation and anti-inflammatory effects, has obvious synergistic treatment effect on acne, and has the effective rate of 100%. And the use is safe, the irritation to skin is small, the adverse reaction is obviously reduced, and especially, the skin inflammation such as pruritus, stinging, stain deposition, redness, swelling, infection and the like can be obviously improved.
Disclosure of Invention
The invention aims to provide a compound chemical stripping skin-changing reagent containing baratinib and application thereof.
Specifically, the invention is realized through the following technical schemes:
in a first aspect, the present invention provides a compound chemical stripping skin-changing agent comprising baratinib, said compound chemical stripping skin-changing agent comprising tartaric acid, phenethyl resorcinol and baratinib.
Preferably, the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass: 10 to 40 mass percent of tartaric acid, 10 to 40 mass percent of phenethyl resorcinol and 0.5 to 2 mass percent of baratinib.
More preferably, the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass: tartaric acid with the mass ratio concentration of 20-40%, phenethyl resorcinol with the mass ratio concentration of 20-40% and baratinib with the mass ratio concentration of 1-2%.
Further preferably, the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass: tartaric acid with a mass ratio concentration of 30% -40%, phenethyl resorcinol with a mass ratio concentration of 25% -35% and baratinib with a mass ratio concentration of 1.5% -2%.
Particularly preferably, the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass: 10% by mass tartaric acid, 10% by mass phenethyl resorcinol and 0.5% by mass baratinib; or 25% by mass tartaric acid, 20% by mass phenethyl resorcinol and 1% by mass baratinib; or 35% by mass tartaric acid, 30% by mass phenethyl resorcinol and 1.5% by mass baratinib; or 40% by mass tartaric acid, 35% by mass phenethyl resorcinol and 2% by mass baratinib.
In the compound chemical stripping skin-changing reagent containing the baratinib, the weight is compensated to 100 percent by adding a solvent for cosmetics or medicines and/or an excipient for cosmetics or medicines.
In the present invention, there is no particular limitation on the type of the cosmetic or pharmaceutical solvent and/or the cosmetic or pharmaceutical excipient, and the cosmetic or pharmaceutical solvent and/or the cosmetic or pharmaceutical excipient commonly used in the art may be used.
Preferably, the cosmetic or pharmaceutical solvent is selected from any one or more of water, alcohol, glycol, and the like.
More preferably, the cosmetic or pharmaceutical solvent is selected from any one or more of distilled water, ethanol, ethylene glycol, propylene glycol, and the like.
Preferably, the cosmetic or pharmaceutical excipient is selected from any one or more of emulsifying agents, preservatives, emollients and the like.
More preferably, the cosmetic or pharmaceutical excipient is selected from any one or more of laureth, isopropyl palmitate, methylparaben, ethylparaben, polydimethylsiloxane 350, and the like.
In a second aspect, the invention provides the use of a compound chemically exfoliating skin-changing agent as described in the first aspect above in the manufacture of a medicament for treating acne.
Compared with the prior art, the invention has the following beneficial effects:
the applicant of the invention discovers that tartaric acid, phenethyl resorcinol and baratinib are combined in a specific proportion, and the tartaric acid, the phenethyl resorcinol and the baratinib show a strong synergistic effect in terms of chemical stripping and skin replacement, so that the concentration of the tartaric acid and the phenethyl resorcinol in a formula can be reduced, a remarkable acne removing and skin replacement effect is obtained, and the composition also has skin whitening, antioxidation and anti-inflammatory effects, has a remarkable treatment effect on acne, and the effective rate reaches 100%. And the use is safe, the irritation to skin is small, the adverse reaction is obviously reduced, and especially, the skin inflammation such as pruritus, stinging, stain deposition, redness, swelling, infection and the like can be obviously improved.
Detailed Description
The following detailed description of the embodiments of the present invention is provided for better illustration of the present invention, but is not to be construed as limiting the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
Example 1: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 10%
Phenethyl resorcinol 10%
Barytinib 0.5%
Distilled water 58%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 1.5%
The preparation method comprises the following steps: weighing the components according to the formula, and dissolving tartaric acid with distilled water to obtain a solution A; then mixing phenethyl resorcinol with propylene glycol, and stirring uniformly to obtain a solution B; and finally, mixing the solution A, the solution B, the baryttinib and the laurinol polyoxyethylene ether, and uniformly stirring to obtain the compound chemical stripping skin-changing reagent.
Example 2: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 25%
Phenethyl resorcinol 20%
Barytinib 1%
Distilled water 32%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as in example 1.
Example 3: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 35%
Phenethyl resorcinol 30%
Barytinib 1.5%
Distilled water 16%
Propylene glycol 15%
Lauryl alcohol polyoxyethylene ether 2.5%
The preparation method is the same as in example 1.
Example 4: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 40%
35% of phenethyl resorcinol
Barytinib 2%
Distilled water 11%
Propylene glycol 10%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as in example 1.
Comparative example 1: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 20%
Barytinib 0.5%
Distilled water 58%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 1.5%
The preparation method comprises the following steps: weighing the components according to the formula, mixing the components, and uniformly stirring to obtain the chemical stripping skin-changing reagent.
Comparative example 2: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 45%
Barytinib 1%
Distilled water 32%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 1.
Comparative example 3: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 65%
Barytinib 1.5%
Distilled water 16%
Propylene glycol 15%
Lauryl alcohol polyoxyethylene ether 2.5%
The preparation method is the same as that of comparative example 1.
Comparative example 4: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 75%
Barytinib 2%
Distilled water 11%
Propylene glycol 10%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 1.
Comparative example 5: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
phenethyl resorcinol 20%
Barytinib 0.5%
Distilled water 58%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 1.5%
The preparation method comprises the following steps: weighing the components according to the formula, mixing the components, and uniformly stirring to obtain the chemical stripping skin-changing reagent.
Comparative example 6: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
45% of phenethyl resorcinol
Barytinib 1%
Distilled water 32%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 5.
Comparative example 7: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
65% of phenethyl resorcinol
Barytinib 1.5%
Distilled water 16%
Propylene glycol 15%
Lauryl alcohol polyoxyethylene ether 2.5%
The preparation method is the same as that of comparative example 5.
Comparative example 8: the chemical stripping skin-changing reagent comprises the following components in percentage by mass:
phenethyl resorcinol 75%
Barytinib 2%
Distilled water 11%
Propylene glycol 10%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 5.
Comparative example 9: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 10%
Phenethyl resorcinol 10%
Distilled water 58.5%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 1.5%
The preparation method comprises the following steps: weighing the components according to the formula, and dissolving tartaric acid with distilled water to obtain a solution A; then mixing phenethyl resorcinol with propylene glycol, and stirring uniformly to obtain a solution B; and finally, mixing the solution A, the solution B and the laurinol polyoxyethylene ether, and uniformly stirring to obtain the compound chemical stripping skin-changing reagent.
Comparative example 10: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 25%
Phenethyl resorcinol 20%
Distilled water 33%
Propylene glycol 20%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 9.
Comparative example 11: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 35%
Phenethyl resorcinol 30%
Distilled water 17.5%
Propylene glycol 15%
Lauryl alcohol polyoxyethylene ether 2.5%
The preparation method is the same as that of comparative example 9.
Comparative example 12: the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass:
tartaric acid 40%
35% of phenethyl resorcinol
Distilled water 13%
Propylene glycol 10%
Lauryl alcohol polyoxyethylene ether 2%
The preparation method is the same as that of comparative example 9.
Example 5: the chemical stripping skin-changing effect of the compound chemical stripping skin-changing reagent of the invention is examined
1. Purpose of experiment
The compound chemical skin stripping and changing agent provided by the invention has the advantages that tartaric acid, phenethyl resorcinol and baratinib are combined in a specific proportion, a stronger synergistic effect is shown in the aspect of chemical skin stripping and changing, and the compound chemical skin stripping and changing agent has a remarkable synergistic effect on treating acne.
2. Experimental method
80 patients with mild-moderate acne on the face (refer to hill sburg and international modified acne powder method for diagnosing mild acne) were selected and divided into four groups of 20, 16-30 years old (average 22 years old) each, 10 men and 10 women each, respectively, treatment group, control group 1, control group 2 and control group 3. Four groups of patients were comparable with no significant differences (P > 0.05) compared to the general clinical data.
Each patient in the treatment group was treated with the compound chemical stripping skin-changing agent of examples 1-4 in sequence for one course of skin-changing treatment. One course of treatment is completed four times, once a week, starting with low concentration and increasing the concentration successively. The compound chemical stripping skin-changing agent of the embodiment 1 is adopted for the first time, a brush dipped with the skin-changing agent starts from the middle part of the face, the skin-changing agent is uniformly and gently smeared from the top to the bottom, the whole face is spread round by round, the serious acne part is smeared, the smeared skin-changing agent is more, the time is about 3-5 minutes, and 5% sodium bicarbonate solution is sprayed on the facial skin of a volunteer after the time to neutralize the skin-changing agent so as to block the action of the skin-changing agent, and then the facial skin is wet-smeared by ice water. The peeling and skin-changing are carried out according to the first skin-changing method by adopting the compound chemical peeling and skin-changing reagent in the embodiment 2 for the second time. And thirdly, peeling off and skin changing is carried out by adopting the compound chemical peeling off and skin changing reagent of the embodiment 3 according to the skin changing method of the first time. The compound chemical stripping skin-changing reagent of the embodiment 4 is adopted for stripping skin-changing according to the first skin-changing method for the fourth time.
Each patient of control group 1 was treated with one course of skin change using the chemical stripping skin change agent of comparative examples 1-4 in sequence. One course of treatment is completed four times, once a week, starting with low concentration and increasing the concentration successively. The skin-changing agent is firstly peeled off by adopting the chemical stripping skin-changing agent of the comparative example 1, the brush dipped with the skin-changing agent is uniformly and gently smeared from the middle part of the face outwards, the skin-changing agent is spread from the inside to the outside round to round, the whole face is smeared, the serious acne part is smeared, the skin-changing agent can be smeared for more than 3 to 5 minutes, and 5 percent sodium bicarbonate solution is sprayed on the facial skin of a volunteer to neutralize the skin-changing agent after the time to block the action of the skin-changing agent, and then the facial skin is wet-smeared by ice water. The skin peeling and changing agent of comparative example 2 was used for the second time to peel and change skin according to the first skin changing method. The skin peeling and changing agent of comparative example 3 was used for the third time to peel and change skin according to the first skin changing method. The fourth time of peeling and skin-changing is performed by adopting the chemical peeling and skin-changing reagent of the comparative example 4 according to the first skin-changing method.
Each patient of control group 2 was treated with one course of skin change using the chemical stripping skin change agent of comparative example 5-comparative example 8 in sequence. One course of treatment is completed four times, once a week, starting with low concentration and increasing the concentration successively. The skin-changing agent is firstly peeled off by adopting the chemical stripping skin-changing agent of the comparative example 5, the brush dipped with the skin-changing agent is uniformly and gently smeared from the middle part of the face outwards, the skin-changing agent is spread from the inside to the outside round to round, the whole face is smeared, the serious acne part is smeared, the skin-changing agent can be smeared for more than 3 to 5 minutes, and 5 percent sodium bicarbonate solution is sprayed on the facial skin of a volunteer to neutralize the skin-changing agent after the time to block the action of the skin-changing agent, and then the facial skin is wet-smeared by ice water. The skin peeling and skin changing is carried out according to the first skin changing method by adopting the chemical peeling and skin changing reagent of the comparative example 6 for the second time. The skin peeling and skin changing is carried out according to the first skin changing method by adopting the chemical peeling and skin changing reagent of the comparative example 7 for the third time. The fourth time of peeling and skin-changing is carried out by adopting the chemical peeling and skin-changing reagent of the comparative example 8 according to the first skin-changing method.
Each patient of the control group 3 was treated with the compound chemical stripping skin-changing agent of comparative example 9-comparative example 12 in sequence for one course of skin-changing treatment. One course of treatment is completed four times, once a week, starting with low concentration and increasing the concentration successively. The compound chemical stripping skin-changing agent of the comparative example 9 is adopted for the first time, a brush dipped with the skin-changing agent starts from the middle part of the face, the skin-changing agent is uniformly and gently smeared from the top to the bottom, the whole face is spread round by round, the serious acne part is smeared, the smeared skin-changing agent is more, the time is about 3 to 5 minutes, and 5 percent sodium bicarbonate solution is sprayed on the facial skin of a volunteer to neutralize the skin-changing agent after the time so as to block the action of the skin-changing agent, and then the facial skin is wet-smeared by ice water. The peeling and skin-changing are carried out according to the first skin-changing method by adopting the compound chemical peeling and skin-changing reagent of the comparative example 10 for the second time. The compound chemical stripping skin-changing reagent of comparative example 11 is adopted for the third time to strip off and change skin according to the first skin-changing method. The fourth time, the compound chemical stripping skin-changing reagent of the comparative example 12 is adopted to strip and change skin according to the first skin-changing method.
3. Evaluation method
Evaluation of acne treatment Effect
The number of facial lesions (pimples, pustules) of four groups of subjects were counted before and after skin change, respectively, and evaluated according to the following evaluation criteria.
Efficacy index = (total skin loss before use-total skin loss after use)/total skin loss before use x 100%;
effective rate = (base healer number + active number)/total number x 100%;
the basic cure is that the curative effect index is more than or equal to 90 percent;
the obvious effect is 60 percent or less, and the curative effect index is less than 90 percent;
the effective rate is 20 percent to less than 60 percent;
the efficacy index is <20%; the evaluation results are shown in Table 1.
Table 1: statistical table of acne treatment effect of each group
Conclusion of experiment: as can be seen from table 1, the compound chemical stripping skin-changing agent provided by the invention has the advantages that tartaric acid, phenethyl resorcinol and baratinib are combined in a specific proportion, a strong synergistic effect is shown in the aspect of chemical stripping skin-changing, the concentration of the tartaric acid and the phenethyl resorcinol in a formula can be reduced, a remarkable acne-removing skin-changing effect is obtained, and a remarkable synergistic effect is achieved for treating acne. It is apparent that the above examples are only illustrative of the present invention and are not limiting of the embodiments of the present invention. Various modifications and alterations of this invention may be made by those skilled in the art without departing from the spirit and scope of this invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (3)
1. The application of the compound chemical stripping skin-changing reagent containing the baratinib in preparing the medicament for treating the acne is characterized in that the compound chemical stripping skin-changing reagent comprises the following components in percentage by mass: 10% by mass tartaric acid, 10% by mass phenethyl resorcinol and 0.5% by mass baratinib.
2. The use according to claim 1, wherein the compound chemical stripping skin-changing agent comprises a pharmaceutically acceptable solvent and an excipient.
3. The use according to claim 2, wherein the pharmaceutically acceptable solvent is selected from any one or more of distilled water, ethanol, ethylene glycol, propylene glycol; the medicinal excipient is selected from one or more of laureth, isopropyl palmitate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate and polydimethylsiloxane 350.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310786370.1A CN116492240B (en) | 2023-06-30 | 2023-06-30 | Compound chemical stripping skin-changing reagent containing baratinib and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310786370.1A CN116492240B (en) | 2023-06-30 | 2023-06-30 | Compound chemical stripping skin-changing reagent containing baratinib and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116492240A CN116492240A (en) | 2023-07-28 |
| CN116492240B true CN116492240B (en) | 2023-09-19 |
Family
ID=87320629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310786370.1A Active CN116492240B (en) | 2023-06-30 | 2023-06-30 | Compound chemical stripping skin-changing reagent containing baratinib and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492240B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771021A (en) * | 2003-05-30 | 2006-05-10 | 詹弗兰科·德·保利·安布罗西 | A formulation for chemical skin-changing |
| CN101791282A (en) * | 2009-12-29 | 2010-08-04 | 广东药学院 | Beauty lotion and preparation method and application thereof |
| CN115068407A (en) * | 2021-03-12 | 2022-09-20 | 浙江万晟药业有限公司 | Baricitinib gel and preparation method and application thereof |
| WO2022259252A1 (en) * | 2021-06-08 | 2022-12-15 | Sol-Gel Technologies Ltd. | Methods of reducing acne and rosacea relapse rate and severity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170182069A1 (en) * | 2015-12-29 | 2017-06-29 | L'oreal | Topically applicable chemical peel composition |
| CN117357429A (en) * | 2016-05-31 | 2024-01-09 | 莱雅公司 | Anti-acne compositions and methods of use |
-
2023
- 2023-06-30 CN CN202310786370.1A patent/CN116492240B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771021A (en) * | 2003-05-30 | 2006-05-10 | 詹弗兰科·德·保利·安布罗西 | A formulation for chemical skin-changing |
| CN101791282A (en) * | 2009-12-29 | 2010-08-04 | 广东药学院 | Beauty lotion and preparation method and application thereof |
| CN115068407A (en) * | 2021-03-12 | 2022-09-20 | 浙江万晟药业有限公司 | Baricitinib gel and preparation method and application thereof |
| WO2022259252A1 (en) * | 2021-06-08 | 2022-12-15 | Sol-Gel Technologies Ltd. | Methods of reducing acne and rosacea relapse rate and severity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116492240A (en) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bazzano et al. | Topical tretinoin for hair growth promotion | |
| US5569651A (en) | Gentle anti-acne composition | |
| CA2301009C (en) | Skin care compositions and use | |
| EP0980243B1 (en) | Use of high dose retinoids for the treatment of photodamaged skin | |
| JP2000501429A (en) | Composition base for topical and cosmetic preparations | |
| US4640932A (en) | Compositions for treating acne vulgaris and methods of making and using same | |
| JP2002506801A (en) | How to reduce cellulite in mammalian skin | |
| EP2319510A1 (en) | Benzoyl peroxide composition for treating skin | |
| US20060222689A1 (en) | Skin care compositions and methods | |
| US3932665A (en) | Process for the treatment of acne vulgaris utilizing retinal | |
| CA2776702C (en) | Topical dapsone for the treatment of acne | |
| US20040228908A1 (en) | Topical composition for transdermal administration | |
| US5853709A (en) | Shaving composition and method for preventing pseudofolliculitis barbae | |
| JPS5921630A (en) | Sebum secretion lowering agent | |
| CN116492240B (en) | Compound chemical stripping skin-changing reagent containing baratinib and application thereof | |
| WO2012140013A2 (en) | New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling. | |
| EP3620213A1 (en) | Retinol oil composition | |
| EP1752132A2 (en) | Skin cosmetic compositions | |
| EP0086228B1 (en) | Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris | |
| Bergfeld | Dermatologic problems in athletes | |
| EP0756479A1 (en) | Gentle anti-acne composition | |
| CN115671022B (en) | Anti-aging microcapsule composition and preparation method and application thereof | |
| KR102571226B1 (en) | Composition for improving scalp condition comprising gluconolactone and climbazole as active ingredients | |
| KR20040043596A (en) | Anti-keratin composition comprising cellulose as a effective component | |
| KR20000018206A (en) | A cosmetic composition of lightening and removing effects in the melanin-like pigmentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |